Ocuphire Pharma, Inc. (OCUP)

Ocuphire Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	19.01	19.05	39.85	0.59	0	0
Revenue Growth (YoY)	-54.30%	-52.20%	6665.70%	-	-	-
Gross Profit	19.01	19.05	39.85	0.59	0	0
Selling, General & Admin	14.34	11.96	7.27	8.12	2.82	1.82
Research & Development	16.81	17.65	14.36	15.17	6.65	2.37
Other Operating Expenses	0	0	0	0	10.5	0
Operating Expenses	31.15	29.61	21.62	23.29	19.97	4.19
Operating Income	-12.14	-10.56	18.23	-22.71	-19.97	-4.19
Interest Expense / Income	0	0	0.01	0	6.85	1.41
Other Expense / Income	-0.85	-0.59	0.01	33.99	-2.2	0.57
Pretax Income	-11.29	-9.97	18.2	-56.69	-24.62	-6.17
Income Tax	0.01	0.01	0.32	0	0	0
Net Income	-11.3	-9.99	17.89	-56.69	-24.62	-6.17
Shares Outstanding (Basic)	25	22	20	15	5	3
Shares Outstanding (Diluted)	25	22	21	15	5	3
Shares Change	17.10%	4.82%	38.68%	218.65%	63.84%	315.53%
EPS (Basic)	-0.48	-0.46	0.90	-3.82	-5.28	-2.17
EPS (Diluted)	-0.49	-0.46	0.87	-3.82	-5.28	-2.17
Free Cash Flow	-3.18	-1.11	14.31	-19.37	-6.8	-3.62
Free Cash Flow Per Share	-0.13	-0.05	0.72	-1.30	-1.46	-1.27
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	-63.86%	-55.45%	45.74%	-3854.84%	-	-
Profit Margin	-59.44%	-52.42%	44.89%	-9625.30%	-	-
Free Cash Flow Margin	-16.74%	-5.84%	35.92%	-3288.62%	-	-
Effective Tax Rate	-	-	1.73%	-	-	-
EBITDA	-11.28	-9.97	18.22	-56.69	-17.77	-4.76
EBITDA Margin	-59.36%	-52.33%	45.71%	-9624.28%	-	-
Depreciation & Amortization	0.01	0.01	0	0	0.01	0
EBIT	-11.29	-9.97	18.21	-56.69	-17.77	-4.76
EBIT Margin	-59.38%	-52.36%	45.70%	-9624.96%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).